Haemophilia

Công bố khoa học tiêu biểu

* Dữ liệu chỉ mang tính chất tham khảo

Sắp xếp:  
Effect of recombinant factor VIIa variant (NN1731) on platelet function, clot structure and force onset time in whole blood from healthy volunteers and haemophilia patients
Haemophilia - Tập 13 Số 5 - Trang 533-541 - 2007
Donald F. Brophy, Erika G. Martin, Melinda E. Nolte, Janice Kuhn, Marcus E. Carr
Summary.  NN1731 is a novel variant of recombinant factor VIIa (rFVIIa) that binds to activated platelets, but has greater enzymatic activity than rFVIIa in generating FXa and thrombin. The effect of NN1731 on clot structure and platelet function was characterized ex vivo in whole blood from healthy volunteers and haemophilic patients. Bloo...... hiện toàn bộ
Rationale for the use of high dose rFVIIa in a high‐titre inhibitor patient with haemophilia B during major orthopaedic procedures
Haemophilia - Tập 7 Số 5 - Trang 517-522 - 2001
Herbert Cooper, Connie P. Jones, Edmund Campion, Barbara A. Konkle, Ulla Hedner
Inhibitor development is a serious complication in patients with haemophilia A and B. Historically, a lack of optimal therapies and factor products for treating inhibitor patients resulted in many patients developing chronic haemophilic arthropathies and flexion contractures of the involved joints. The introduction of immune‐tolerance protocols to eradicate high‐titre inhibitors has greatl...... hiện toàn bộ
Enhancement of factor VIIa haemostatic efficacy by formulation with PEGylated liposomes
Haemophilia - Tập 14 Số 3 - Trang 476-483 - 2008
Rivka Yatuv, I. DAYAN, Lea Carmel-Goren, Micah Robinson, Irit Aviv, Mirela Goldenberg-Furmanov, Moshe Baru
Summary.  Recombinant activated factor VII (rFVIIa) is an effective treatment of the haemophilia patient with inhibitors and acquired haemophilia. However, on account of its relatively short half‐life (HL), achieving therapeutic efficacy with FVIIa requires repeated injections. The development of a long‐acting FVIIa product would therefore be beneficial. The formulat...... hiện toàn bộ
Prolonged effect of a new O-glycoPEGylated FVIII (N8-GP) in a murine saphenous vein bleeding model
Haemophilia - Tập 19 Số 6 - Trang 913-919 - 2013
A. E. Pastoft, Mirella Ezban, Mikael Tranholm, Jens Lykkesfeldt, Brian Lauritzen
Improvement of national blood safety profile: effect of contract fractionation of plasma in resource limited countries, the Moroccan experience
Haemophilia - Tập 20 Số 5 - 2014
S. Boulahdid, A. Benahadi, B. Adouani, A. Laouina, Fatna El Mehdaoui, A. Mokhtari, Abdelmajid Soulaymani, K. Hajjout, Reza Alami
Sites of initial bleeding episodes, mode of delivery and age of diagnosis in babies with haemophilia diagnosed before the age of 2 years: a report from The Centers for Disease Control and Prevention’s (CDC) Universal Data Collection (UDC) project
Haemophilia - Tập 15 Số 6 - Trang 1281-1290 - 2009
Roshni Kulkarni, J. Michael Soucie, Jeanne M. Lusher, Rodney Presley, Amy D. Shapiro, M. John Gill, Marilyn J. Manco‐Johnson, Marion A. Koerper, Prasad Mathew, Thomas C. Abshire, Donna DiMichele, Keith Hoots, Robert L. Janco, Diane J. Nugent, S. Geraghty, Bruce L. Evatt
Summary.  Lack of detailed natural history and outcomes data for neonates and toddlers with haemophilia hampers the provision of optimal management of the disorder. We report an analysis of prospective data collected from 580 neonates and toddlers aged 0–2 years with haemophilia enrolled in the Universal Data Collection (UDC) surveillance project of the Centers for D...... hiện toàn bộ
Guideline on the selection and use of therapeutic products to treat haemophilia and other hereditary bleeding disorders
Haemophilia - Tập 14 Số 4 - Trang 671-684 - 2008
David Keeling, Robert C. Tait, Michael Makris
Summary.  Evidence‐based guidelines are presented on the selection and use of therapeutic products to treat haemophilia and other hereditary bleeding disorders. They include details of therapeutic products available in the UK and they update and replace previous United Kingdom Haemophilia Centre Doctors’ Organisation guidelines.
Multimodal blood loss prevention approach including intra‐articular tranexamic acid in primary total knee arthroplasty for patients with severe haemophilia A
Haemophilia - Tập 22 Số 4 - 2016
E. Carlos Rodríguez‐Merchán, J. A. Romero‐Garrido, Primitivo Gómez-Cardero
Bone marrow mesenchymal cells for haemophilia A gene therapy using retroviral vectors with modified long‐terminal repeats
Haemophilia - Tập 9 Số 1 - Trang 94-103 - 2003
An Van Damme, Marinee Chuah, Francesco Dell’Accio, Cosimo De Bari, Frank P. Luyten, Peter Carmeliet, Thierry VandenDriessche
Summary. Bone marrow (BM) cells are attractive target cells for ex vivo gene therapy of genetic diseases, including haemophilia A. However, BM‐derived haematopoietic stem/progenitor cells (HSCs) transduced with factor VIII (FVIII) retroviral vectors, failed to express FVIII in vivo. To overcome the limitations of ...... hiện toàn bộ
Rare coagulation deficiencies
Haemophilia - Tập 8 Số 3 - Trang 308-321 - 2002
Flora Peyvandi, Stefano Duga, Sepideh Akhavan, Pier Mannuccio Mannucci
Summary.  Deficiencies of coagulation factors (other than factor VIII and factor IX) that cause a bleeding disorder are inherited as autosomal recessive traits and are generally rare, with prevalences in the general population varying between 1 : 500 000 and 1 : 2 000 000. In the last few years, the number of patients with recessively transmitted coagulation deficien...... hiện toàn bộ
Tổng số: 34   
  • 1
  • 2
  • 3
  • 4